1
Deen Keith Charles, Young Peter Ronald: Tumor necrosis factor related receptor, tr6. Smithkline Beecham, October 14, 1998: EP0870827-A2 (58 worldwide citation)

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemi ...


2
MCLURE Kevin G, YOUNG Peter Ronald: [fr] TRAITEMENT DE MALADIES PAR LA RÉGULATION ÉPIGÉNÉTIQUE, [en] TREATMENT OF DISEASES BY EPIGENETIC REGULATION. RVX THERAPEUTICS, October 24, 2013: WO/2013/156869 (23 worldwide citation)

[en] The present application is directed to the use of substituted 2-phenyl-3H-quinazolin-4-ones and analogs for inhibiting BET (bromodomain and extra terminal domain) proteins. The disclosed compounds can be used for the treatment of cancers that exhibit c-myc overexpression, cancers that overexpre ...


3
Mcdonnel Peter Colon, Young Peter Ronald: Drug binding protein. Smithkline Beecham, June 16, 1999: EP0922762-A1 (19 worldwide citation)

This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein CSBP beta , to a gene encoding same and to assays and sc ...


4

5
Mclaughlin Megan Mchale, Kumar Sanjay, Livi George Petro, Young Peter Ronald: Methods of the identification of pharmaceutically active compounds. Smithkline Beecham, July 12, 2000: EP1017980-A2

CSBP/p38 is a MAP kinase that is activated in response to stress, endotoxin, interleukin 1 and tumor necrosis factor. Using a catalytically inactive mutant (D168A) of human CSBP2 as the bait in a yeast two-hybrid screen, a kinase has been cloned which shares SIMILAR 70 % amino acid identity to MAPKA ...


6
Young Peter Ronald, Erickson Miller Connie L: Method for obtaining receptor agonist antibodies. Smithkline Beecham, October 21, 1998: EP0871477-A1

PCT No. PCT/US96/09613 Sec. 371 Date Jan. 28, 1997 Sec. 102(e) Date Jan. 28, 1997 PCT Filed Jun. 7, 1996 PCT Pub. No. WO96/40231 PCT Pub. Date Dec. 19, 1996Monoclonal antibodies to the erythropoietin receptor are disclosed.


7

8
Lee John Cheung Lun, Adams Jerry Leroy, Gallagher Timothy Francis, Green David W, Heys John Richard, Mcdonnell Peter Colon, Mcnulty Dean Edward, Strickler James E, Young Peter Ronald: Proteine de liaison de medicament, Drug binding protein. Smithkline Beecham Corporation, Smithkline Beecham Corporation, GOWLING LAFLEUR HENDERSON, March 23, 1995: CA2171982

This invention relates to drug binding proteins, to genes encoding same and to a ssays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflamm atory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens use ...


9

10
Krasney Philip A, Young Peter Ronald: Il-1 inhibitors. Smithkline Beecham Corporation, Krasney Philip A, Young Peter Ronald, sDINNER Dara L, October 1, 1992: WO/1992/016226

The present invention provides for a novel mechanism of controlling anti-inflammatory activity in a mammal, including humans. The inhibition of P-glycoprotein mediated transport of Interleukin-1 (IL-1) from cells, by an inhibitor of the mdr P-glycoprotein, provides for treatment of indications in wh ...